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Abstract 
Background: B cells have been demonstrated to have critical roles in developing 
autoimmune bullous diseases. Recently identified tumor necrosis factor-like molecules, 
B cell-activating factor of the TNF family (BAFF) and a proliferation-inducing ligand 
(APRIL) are essential molecules for B cell development, survival, and proliferation. 
Although the functions of APRIL have not been fully evaluated, recent studies suggest 
that circulating levels of APRIL are increased in various autoimmune diseases, 
including systemic lupus erythematosus and rheumatoid arthritis.  
Objectives: To determine serum APRIL levels in patients with pemphigus vulgaris 
(PV) and bullous pemphigoid (BP), and compare those with clinical findings and 
laboratory findings. 
Patients/Methods: Sera from 15 PV patients, 43 BP patients, and 15 normal controls 
were subjected to ELISA assays to measure serum APRIL, BAFF, Dsg3, and BP180 
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levels. 
Results and Conclusions: Circulating APRIL levels were significantly elevated in BP 
patients but not in PV patients, and correlated with serum BAFF levels. Our study 
revealed that serum APRIL levels tended to be increased in the quite early stage of 
disease. In conclusion, circulating APRIL levels may be a useful marker for early 
activation of autoimmune diathesis, and furthermore, an effective therapeutic target 
molecule in patients with BP. 
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Introduction 
Autoimmune bullous diseases are characterized by autoantibodies against specific 
adhesion molecules of the skin and/or mucous membrane. For instance, patients with 
pemphigus vulgaris (PV) carry autoantibodies specific to a desmosomal protein 
desmoglein 3 (Dsg3), while bullous pemphigoid (BP) is distinguished by autoantibodies 
directed against a hemidesmosomal protein called BP180. Although these 
autoantibodies are widely known to play a primary role in the disease 
manifestation[1-5], both in animal models and human, it remains unknown how these 
disease-specific autoreactive B cells and autoantibodies are induced. 
Recent evaluation on the role of B cells in autoimmune diseases has indicated that B 
cells have more critical functions in regulating immune responses than just the 
precursors of antibody-secreting cells. Furthermore, B cell depletion therapy with 
anti-CD20 monoclonal antibody turned out to be effective in the management of 
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autoimmune diseases, including autoimmune blistering diseases[6-19]. Several studies 
have also demonstrated that cytokines, such as tumor necrosis factor (TNF)-α, play 
important roles in these blistering diseases, supported by the validity of the treatment 
with monoclonal anti-TNF-α antibodies in severe PV[20, 21]. 
Recently identified two TNF family molecules, B cell-activating factor of the TNF 
family (BAFF) and a proliferation-inducing ligand (APRIL), have received increasing 
attention as key regulators of normal B cell functions and autoimmune B cell 
induction[22]. BAFF is an essential factor for B cell survival, and its three receptors, 
transmembrane activator and calcium modulator ligand interactor (TACI), B cell 
maturation antigen (BCMA), and BAFF receptor (BAFF-R), are variably expressed on 
B cells during their differentiation[23]. APRIL is homologous to BAFF, but binds only 
to TACI and BCMA.  APRIL shares many functions in common with BAFF, while 
they also have still distinct functions [24-26]. Notably, serum levels of BAFF and 
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APRIL are increased in autoimmune diseases, including SLE and rheumatoid 
arthritis[27, 28], and blockade of BAFF and APRIL prevents autoimmunity in animal 
models of disease[29-32] and is being developed for human use[33]. 
Accordingly, it is considered important to examine the correlation between bullous 
diseases and BAFF/APRIL system to infer the function of these TNF family molecules 
in the process of skin blistering diseases, and to suggest the efficacy of BAFF and/or 
APRIL-targeting therapy in these skin disorders. Recently, we have demonstrated that 
serum BAFF levels are increased in BP patients[34]. In this study, we determined serum 
APRIL levels of the patients with PV and BP, and compared them with BAFF as well as 
other clinical findings. Serum APRIL levels were elevated in BP patients and closely 
correlated with serum BAFF levels, suggesting a role of BAFF/APRIL system in the 
disease development.  
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Materials and Methods 
Patients and clinical assessment 
This analysis includes 15 patients with PV (8 males and 7 females) and 43 patients 
with BP (20 males and 23 females) who visited Tokyo University Hospital from January 
1985 to August 2006, and 15 normal controls (NC, 7 males and 8 females). Their ages 
(mean±SD) were as follows: PV patients were 57.1±13.1 (range from 26 to 74), BP, 
70.0±16.4 (range from 17 to 93), and NC, 52.5±22.7 (range from 24 to 88) years old. 
There was no evident difference of sex among the three groups, and BP patients turned 
out to be significantly older than the other two groups (p<0.05) by Kruskal Wallis 
one-way analysis of variance (ANOVA) and Dunn’s test. Blood samples were obtained 
from patients with clinically active PV or BP, i.e., patients who had been diagnosfed as 
PV or BP respectively, but not yet received systemic corticosteroid and/or other 
immunosuppressive treatments. 
 - 9 - 
Diagnosis of PV was based on the following criteria[35]: characteristic clinical 
findings of mucous membrane ulcerations and /or multiple fragile vesiculobullous 
lesions of the skin; histological evidence of intraepithelial acantholysis; evidence of 
in-vivo bound IgG autoantibodies on the cell surfaces of affected epithelium by direct 
immunofluorescence; evidence of circulating antiepithelial autoantibodies by indirect 
immunofluorescence; and autoantibodies specific to Dsg3 by immunochemical 
techniques. Diagnosis of BP was based on the following criteria[35]: characteristic 
clinical findings of pruritic plaques and tense blisters of the trunk and extremities; 
histological evidence of subepidermal blisterings with many infiltrating 
polymorphonuclear cells, especially eosinophils, along the basal membrane and within 
the blister cavity; in-vivo linear IgG and/or C3 deposits at the dermoepidermal junction 
by direct immunofluorescence, evidence of circulating autoantibodies to the basement 
membrane zone by indirect immunofluorescence, and autoantibodies specific to BP180 
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by immunochemical techniques. Patients and healthy volunteers gave consent to 
participate in this study, which has been approved by the institutional review board. 
Disease duration was defined as the time period from the onset of symptoms till 
diagnosis. 
 
ELISA assays for detection of human soluble APRIL, BAFF, anti-Dsg3 antibodies, 
and anti-BP180 antibodies 
Serum APRIL levels were measured using human APRIL EIA kit (IBL, Takasaki, 
Japan) according to the manufacturer’s protocol. Briefly, standards and serum samples 
were added to microplate wells pre-coated with mouse monoclonal antibodies specific 
for human APRIL. Next, biotin-conjugated polyclonal anti-APRIL antibodies, and then 
HRP-conjugated streptavidin, were added to the wells after rinsing any unbound 
substances at each step. Following color development with TMB substrate solution and 
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1 M phosphoric acid, absorbance of each well was read using a microplate reader set to 
450 nm. Similarly, human BAFF/BlyS/TNFSF13B immunoassay kit (R&D Systems, 
Minneapolis, MN, USA) was used for detection of serum BAFF levels, anti-Dsg3 
ELISA kit (Mesacup Desmoglein Test “Dsg3”, MBL, Nagoya, Japan) for the serum 
titers of anti-Dsg3 antibodies, and BP180 ELISA kit (MBL) for anti-BP180 antibodies, 
according to the manufacturer’s protocol. 
 
Indirect immunofluorescence analysis 
Normal human skin was taken from healthy volunteers, who had also given consent to 
participate in this study, and frozen in OTC compound (Sakura Fineteck, Torrance, CA). 
Cryostat-cut tissue sections were fixed, blocked, and then incubated with patients’ sera 
diluted 1:20, 40, 80, 160, and 320 with PBS (20min, 37˚C). After washing, the sections 
were incubated sequentially with FITC-conjugated anti-human IgG antibody (BD 
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PharMingen, San Diego, CA) at predetermined optimal concentration (20min, 37˚C). 
The autoantibody titer at which IgG deposition to the intracellular space or BMZ was 
demonstrated, was depicted as indirect immunofluorescence dilution index.
 
Statistical analyses 
Statistical analyses of serum APRIL levels among the three groups were performed 
using Kruskal Wallis one-way analysis of variance (ANOVA) and then Dunn’s test was 
applied because the data of BP patients’ serum APRIL levels were not strictly normally 
distributed. Correlations between serum APRIL and serum autoantibody titers, blood 
eosinophil number, serum LDH level, serum IgE level, serum IgA level, serum BAFF 
levels, disease duration, indirect immunofluorescence dilution index, and extent of skin 
lesion, that is, the extent of skin blistering, erosive, or erythematous lesion (which was 
decided in a blinded way), were analyzed with Spearman’s correlation coefficient by 
 - 13 - 
rank test. A p-value less than 0.05 was considered statistically significant.  
 - 14 - 
Results 
Serum APRIL levels were elevated in the patients with PV and BP 
Serum APRIL levels were measured by ELISA in PV patients, BP patients, and NC. 
Median (first, third quantile) of serum APRIL levels was, 7.84 (0, 15.35) ng/ml in NC 
group, 19.36 (0, 27.79) ng/ml in PV patients, and 20.31 (6.19, 64.36) ng/ml in BP 
patients (Figure 1). Statistical analysis revealed significant differences between the 
groups (ANOVA; p < 0.05, df = 2). Serum APRIL levels in BP patients were 
significantly higher than those in NC (Dunn's test; p < 0.05). Although PV patients also 
tended to have higher levels of APRIL than NC, there was no significant difference. 
When values higher than third quantile of NC group (15.35 ng/ml) were considered to 
be elevated, serum APRIL levels were elevated in 66.7% (10/15) of PV and 58.1% 
(25/43) of BP patients. In BP patients, there was no correlation between serum APRIL 
levels and sex, age, or complications found, including internal malignancy (data not 
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shown). Accordingly, it can be concluded that BP patients had significantly elevated 
serum levels of APRIL.  
 
Serum APRIL levels were elevated in the early stage of BP disease 
We next analyzed the relationship between serum APRIL levels and clinical findings 
in BP patients. However, there was no significant association with blood eosinophil 
number, serum LDH level, serum IgE level, serum IgA level, extent of skin lesion, or 
reactivity to treatment (Figure 2A, B, and data not shown). 
We then investigated the direct role of APRIL on pathogenic antibody production in 
BP. However, in respect of anti-BP180 antibody levels determined by ELISA, there was 
no evident correlation with APRIL levels (Figure 2C), nor was indirect 
immunofluorescence dilution index (data not shown). Also in PV patients, no 
correlation was found between serum APRIL levels and anti-Dsg3 antibody levels (data 
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not shown). 
By contrast, there found a significant negative correlation between serum APRIL 
levels and disease duration in BP patients, that is, the patients in the shorter period from 
BP onset turned out to carry significantly higher levels of serum APRIL than those with 
longer disease duration (Figure 2D, r=-0. 55, p < 0.001). Meanwhile, there was no 
statistical correlation proven between serum APRIL levels and disease durations in PV 
patients (data not shown). Attending to BP, serum APRIL levels were longitudinally 
assessed in three BP patients treated with oral corticosteroid (Figure 2E). In patients 1 
and 2, serum APRIL levels were highest in the early point and decreased immediately, 
to normal level in patient 1, while anti-BP180 antibody levels were still higher after 
APRIL declined. It is interesting to note that serum APRIL level was already elevated 
even before skin lesion emerged in patient 3. This patient experienced recurrence on day 
53 through the disease course. Unfortunately, we could not follow up the serum APRIL 
 - 17 - 
or anti-BP180 antibody levels of disease-free period due to the absence of preserved 
sera. However, at least, all the three patients found in Figure 2E showed the highest 
levels of serum APRIL at the earliest point of investigation. In addition, the elevation of 
anti-BP180 antibody levels delayed those of APRIL levels in all the three patients. 
Especially in patient 1 and 2, anti-BP180 antibody levels were still higher even after 
skin lesion almost disappeared. While, APRIL levels decreased along with improved 
disease activity in all the patients. These data may suggest that serum APRIL levels tend 
to reflect the disease activity more subtly than anti-BP180 antibody titers in patients 
with BP.  
 
APRIL levels correlated with BAFF levels in sera of BP patients 
Association of serum APRIL levels with the same TNF family BAFF levels was also 
examined. As shown in Figure 3, serum APRIL levels in BP patients showed a positive 
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correlation with serum BAFF levels (r=0.46, p<0.01). Thus, most patients with high 
levels of serum APRIL also had elevated serum BAFF levels, suggesting that elevation 
of BAFF and APRIL may result from common mechanisms. In respect of PV patients, 
however, we did not detect significant correlation between serum APRIL and BAFF 
levels (data not shown).
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Discussion 
In the current study, we demonstrated that serum APRIL levels were elevated in 
patients with BP. This is the first report demonstrating elevated serum APRIL levels in 
organ-specific autoimmune diseases. Although there was no statistical relationship 
proven between serum APRIL levels and anti-BP180 antibody titers (Figure 2C), 
longitudinal analysis in three BP patients suggested that serum APRIL levels tended to 
be high in the early stage of disease and reduced in response to treatment with oral 
corticosteroid, ahead of the changes in anti-BP180 antibody titiers (Figure 2E). In 
especial, serum APRIL level of patient 3 turned out to have been elevated even before 
the manifestation of skin lesion. Furthermore, while serum APRIL levels decreased 
rapidly, anti-BP180 antibody titers remained higher even after serum APRIL levels 
declined. In patient 2, we unfortunately could not follow up the change of anti-BP180 
antibody titers or serum APRIL levels from day 14 to day 529, due to the absence of 
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sera. Accordingly, we were not able to decide whether anti-BP180 antibody titer kept 
high or once reduced. There was no recurrence experienced through disease course, thus, 
the high titer of anti-BP180 antibody did not affect directly to disease continuance or 
recurrence. Rather, as regarding patient 2, serum APRIL levels may reflect properly the 
disease activity. Therefore, although these results do not prove that elevations in serum 
APRIL alone cause clinical symptoms, APRIL is assumed, at least, to participate in 
production of anti-BP180 antibodies, conductive to BP manifestation. 
These features in longitudinal change of serum APRIL levels are quite similar with 
that of the same TNF family member BAFF levels. In respect of BAFF, the same 
distinction was reported recently in SLE[27]. Elevated BAFF levels preceded the formal 
fulfillment of criteria for SLE, suggesting the efficacy of BAFF as a marker for early 
activation of autoimmune diathesis. Adding our data, APRIL also has prospects of 
carrying the similar validity to evaluate autoimmune activity in the early stage. This is 
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supported by the result that serum APRIL levels were significantly higher in the patients 
with shorter duration of BP disease (Figure 2D). 
 While serum APRIL and BAFF levels correlated with each other in the majority of 
patients with BP (Figure 3), some patients carried high APRIL level and low BAFF 
level, and others expressed inverse data. As for these patients with ‘mismatched’ value, 
no evident character was found in either pathogenic anti-BP180 antibody level or 
disease activity markers. Despite similar structure, shared receptor-specificity, and 
overlapping features as the same TNF superfamilies, BAFF and APRIL have distinct 
functions. APRIL appears to play a role in T-cell-independent type II antigen responses 
and T-cell survival, while BAFF induces B-cell proliferation and differentiation[25, 26]. 
In a murine SLE model NZB/W F1, blockade of BAFF alone, and both BAFF and 
APRIL, exhibited similar effects, including B cell and B cell subset depletion, and 
prevention of the progressive T cell activation and dendritic cell accumulation. 
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Meanwhile, inhibition of both BAFF and APRIL, but not BAFF alone, reduced the 
serum levels of IgM antibodies, decreased the frequency of plasma cells in the spleen, 
and inhibited the IgM response to a T cell-dependent antigen[24]. We did not find any 
characteristics reflecting these functional differences of BAFF and APRIL in BP 
patients. Presumably, main role of both BAFF and APRIL in manifestation of BP is 
quite similar, that is, involvement in early activation of self-antigen-driven B and T cells 
along with loss of tolerance. Actually, APRIL and BAFF are reported to form active 
heterotrimeric molecules when coexpressed, in addition to homotrimeric molecules that 
is common to TNF superfamily, and the circulating heterotrimers are recognized in the 
sera of patients with systemic immune-based rheumatic disease[36]. Thus, both APRIL 
and BAFF may play a role, in consort with each other, in autoimmune disorders through 
the active BAFF/APRIL heterotrimers. Although only BAFF, not APRIL, contributes to 
B cell class-switch leading to production of pathogenic IgG autoantibodies, other 
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additional factors might determine progression and elongation of autoimmune diseases. 
Leastwise, still quite small number of patients attended to this study, so that 
accumulation of patients might be able to explain any functional segregation in the 
autoimmune skin blistering disorders. 
As for serum immunoglobulin levels, in addition, serum IgA levels are reported to be 
significantly decreased in APRIL knock out mice[37], suggesting that APRIL promotes 
IgA class switching. In fact, TACI, the common receptor of BAFF and APRIL, and 
BAFF-R are important for transducing signals that result in isotype switching in B cells 
to IgG1, IgA, and IgE[38]. In our study, there was no correlation found between serum 
APRIL level and serum IgA or IgE level (Figure 2A and data not shown). So as to 
further elucidate the role of APRIL in the manifestation of BP, it would be interesting to 
examine the detailed correlation between serum APRIL levels and especially serum IgA 
levels, during disease course.
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While serum APRIL levels were significantly elevated in BP patients, and were 
correlated with disease durations, we did not find the similar statistical relationship in 
patients with PV. While it may indicate that the factors involved in the induction of PV 
and BP are different, this may be because of the disease duration in PV patients. While 
serum APRIL levels were proved to be higher in patients with shorter disease duration 
in BP patients, PV patients that we were able to examine carried longer disease duration 
than BP patients (mean; 3.5 months in PV). Therefore, the assessment of early time 
points in PV patients will be necessary to determine more exact relation between serum 
APRIL and pemphigus. In regard to other factors explaining the difference between BP 
and PV, for instance, elevated eosinophil and neutrophil number both in circulating 
blood and skin blistering lesion is more frequently seen in BP patients, rather than PV 
patients. The activation of these cells may be through T-cell mediated inflammatory 
reactions. These augmented T cell functions may have respect to some APRIL 
 - 25 - 
functions.
 In summary, serum APRIL levels were increased in BP patients. APRIL tended to 
altitude in the early phase of disease, preceding the elevation of pathogenic anti-BP180 
antibodies especially in patient 1 and 3 in Figure 2E. This change of APRIL along 
disease course is similar with that of BAFF, indicating the overlapping roles in disease 
activation. These results suggest that APRIL may predict not only first onset but also 
recurrence of BP, and that blockade of BAFF/APRIL system may be potential 
therapeutic targets in this autoimmune bullous disorder. 
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Figure legends 
Figure 1. Serum levels of APRIL measured by ELISA in 15 patients with PV, 43 with 
BP, and 15 normal controls (NC). The measured values from individual patients were 
plotted by dots. *p < 0.05 by Kruskal Wallis test followed by Dunn’s test. 
 
Figure 2: A-C: The correlation of serum APRIL levels with blood eosinophil number 
(A), extent of skin lesion (B), anti-BP180 antibody titer (C), and disease duration (D) in 
patients with BP. In C, anti-BP180 antibody levels were determined by ELISA. E: 
Longitudinal analysis of the serum APRIL and anti-BP180 antibody levels in three 
patients with BP. The arrows indicated in each figure show the period when oral 
corticosteroid treatment was started. The curved lines colored gray mean relative extent 
of skin lesion.  
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Figure 3. The correlation of serum APRIL levels with serum BAFF levels in BP 
patients. 
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